January 13, 2021 After a big year, biotech flotations have much to do Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
November 26, 2020 Ash 2020 cell therapy preview – the battle for recognition With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
April 28, 2020 AACR 2020 – Gracell validates a novel Car-T target The Chinese group sees responses in all five subjects treated with its allogeneic anti-CD7 Car-T therapy.
April 22, 2020 AACR 2020 preview – no Tigit, but plenty of novel mechanisms Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.